

Date and Time: *Tuesday 12 April 2016, 10:00-16:00*

Minutes: Confirmed

ADHD Guideline Committee (GC) Meeting 1

Place: *Boardroom, National Guideline Centre, 180 Great Portland Street, London W1W 5QZ*

Present:

Gillian Baird (GB)	Professor of Paediatric Neurodisability and Consultant Developmental Paediatrician, Chair
Emily Simonoff (ES)	Professor of Child and Adolescent Psychiatry, Clinical Specialist
Marios Adamou (MA)	Consultant Psychiatrist (adults) and Visiting Professor
Philip Asherson (PA)	Professor of Psychiatry and Honorary Consultant Psychiatrist
Polly Branney (PB)	General Practitioner
Chris Hollis (CH)	Professor of Child and Adolescent Psychiatry and Consultant in Developmental Neuropsychiatry
Nicole Horwitz (NH)	Consultant Community Paediatrician
Jen Lewis-Neill (JLN)	Clinical Lead/Independent Nurse prescriber
Jonathan Rackham (JR)	Lay Member
David Traxson (DT)	Educational Psychologist
Ian Wong (IW)	Professor of Pharmacy Practice and Medicine Evaluation
Susan Young (SY)	Clinical Senior Lecturer in Psychology and Honorary Consultant Clinical/Forensic Psychologist

NGC technical team

Joanna Ashe (JA)	Information Scientist
Rebecca Boffa (RB)	Research Fellow
Katie Broomfield (KB)	Document Editor/Process Assistant (notes)
Margaret Constanti (MC)	Senior Health Economist
Samantha Jones (SJ)	Project Manager (item 1 only)
Kate Kelley (KK)	Guideline Lead

NICE

Ben Doak (BD)	Guidelines Commissioning Manager
Jessica Fielding (JF)	Public Involvement Advisor

Apologies

Caroline Farmer (CF)	Senior Research Fellow
Jean Fitzpatrick (JF)	Lay Member
Kapil Sayal (KS)	Professor of Child & Adolescent Psychiatry and Honorary Consultant Psychiatrist
Jody Warner-Rogers (JWR)	Consultant Clinical Psychologist and Paediatric Neuropsychologist

Notes

1. The Chair welcomed the group to the first meeting of this GC and introductions were made. Apologies were received from CF, JF, KS and JWR.
2. The Chair reviewed and requested updates to the declarations of interest register. The Chair declared that in relation to previous declarations recorded in the DOI register, for this meeting, no action applies. The following new declarations of interest were received for this GC meeting:

GC Declarations of Interest			
N.B. The Chair and GC members were recruited to this guideline using NICE DOI policy published September 2014.			
Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chair's action
PB	On the committee for a meeting sponsored by Novartis entitled the management of ADHD in adults, for which payment was received.	Personal financial specific	Declare and withdraw
	Set up an ADHD clinic in Oxford (as a limited company) in 2015. This is a private clinic but all of the consultants are subcontracted and work full-time for the NHS (A CAMHS consultant, adult psychiatrist and paediatrician).	Personal financial non-specific	Declare and participate
CH	In receipt of EU grants to develop and test a transformative platform of remote monitoring of disease state in three CNS diseases: epilepsy, multiple sclerosis and depression. Janssen Pharmaceuticals are the research partner and the money is attributable to the University of Nottingham.	Non-personal financial non-specific	Declare and participate
	Authors blogs on ADHD. Last blog post was in March 2016 on methylphenidate for ADHD.	Personal non-financial specific	Declare and participate
MA	Member of the European Network Adult ADHD.	Personal non-financial specific	Declare and participate
SY	President of the UK ADHD Partnership.	Personal non-financial specific	Declare and participate
	Vice President of the UK Adult ADHD Network.	Personal non-financial specific	Declare and participate
	Trustee of the ADHD foundation.	Personal non-financial specific	Declare and participate
	Director of Psychology Services.	Personal financial specific	Declare and withdraw
ES	Chair of the European ADHD	Personal non-	Declare and

	<p>Guidelines Group (EAGG).</p> <p>Member of the European network of hyperactivity disorders.</p> <p>Corresponding author on a submission to the BMJ (from the European ADHD Guidelines Group) arguing against a recent systematic review by Storebo et al (2015) and stating the available evidence supports the efficacy and safety of methylphenidate for the treatment of ADHD.</p> <p>Collaborating in a network meta-analysis of pharmacological interventions for ADHD, which is likely to overlap with work undertaken by NICE.</p>	<p>financial specific</p> <p>Personal non-financial specific</p> <p>Non-personal non-financial specific</p> <p>Personal non-financial specific</p>	<p>participate</p> <p>Declare and participate</p> <p>Declare and participate</p> <p>Declare and participate</p>
<p>NICE DOI policy classifications are:</p> <ul style="list-style-type: none"> • Personal financial specific • Personal financial non-specific • Personal non-financial specific • Personal non-financial non-specific • Non-personal financial specific • Non-personal financial non-specific 			

3. KK gave a presentation on the NGC guidelines programme and NICE declaration of interests policy.
4. BD gave a presentation on the role of the Guideline Commissioning Manager (GCM).
5. JF gave a presentation on patient and carer involvement in guideline development.
6. JA gave a presentation on searching for the evidence.
7. MC gave a presentation on health economics.
8. GB gave a presentation on the scope and review questions.
9. KK gave a presentation on reviewing the evidence.
10. KK led a discussion on the protocol for pharmacological treatment in adults.
11. KK led a discussion on the protocol for pharmacological treatment in children.
12. AOB: the group discussed next steps and agreed action points.

Date, time and venue of the next meeting

GC2: Tuesday 24 May 2016, Donald Hunter Room, Royal College of Physicians